Market Spotlight: Dry Eye Disease
Market Spotlight: Dry Eye Disease
$1,318.00
This Market Spotlight report covers the Dry Eye Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Dry Eye Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were 1.54 billion prevalent cases of dry eye disease worldwide, and forecasts that number to increase to 1.72 billion prevalent cases by 2029.
- The approved drugs in the dry eye space focus on a wide variety of targets. The majority of approved drugs are administered via the topical route, with the remainder being intraocular/subretinal/subconjunctival and intranasal formulations.
- The majority of industry-sponsored drugs in active clinical development for dry eye are in Phase II. Therapies in development for dry eye focus on a wide variety of targets. The majority of pipeline drugs are administered via the topical route.
- High-impact upcoming events for drugs in the dry eye space comprise topline Phase II, Phase II/III, and Phase III trial results. The overall likelihood of approval of a Phase I dry eye asset is 11.6%, and the average probability a drug advances from Phase III is 31.3%. Drugs, on average, take 8.5 years from Phase I to approval, compared to 8.8 years in the overall ophthalmology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for dry eye have been in the late phases of development, with 58% of trials in Phase III–IV compared to 42% in Phase I–II.
- The US has a substantial lead in the number of dry eye clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the dry eye space is dominated by completed trials. Novartis has the highest number of completed clinical trials for dry eye, with 81 trials.
- Novartis leads industry sponsors with the highest overall number of clinical trials for dry eye, followed by AbbVie
CONTENTS
7 OVERVIEW
8 KEY TAKEAWAYS
9 DISEASE BACKGROUND
9 Definition
9 Patient segmentation
10 Symptoms
10 Risk factors
10 Diagnosis
11 TREATMENT
11 Ocular lubricants
11 Prescription drugs
12 Eyelid hygiene
13 Surgical treatment
14 EPIDEMIOLOGY
18 MARKETED DRUGS
21 PIPELINE DRUGS
29 RECENT EVENTS AND ANALYST OPINION
29 ST-100 for Dry Eye (January 3, 2022)
30 CyclASol for Dry Eye (December 21, 2021)
31 OTX-DED for Dry Eye (December 6, 2021)
32 OTX-CSI for Dry Eye (October 22, 2021)
34 NovaTears for Dry Eye (September 30, 2021)
35 AR-15512 for Dry Eye (September 15, 2021)
37 NovaTears for Dry Eye (April 13, 2021)
39 RGN-259 for Dry Eye (March 18, 2021)
41 Visomitin for Dry Eye (February 22, 2021)
43 CyclASol for Dry Eye (January 11, 2021)
44 Reproxalap for Dry Eye (January 7, 2021)
46 NovaTears for Dry Eye (December 22, 2020)
48 PL-9643 for Dry Eye (December 15, 2020)
49 Voclosporin Ophthalmic Solution (VOS) for Dry Eye (November 2, 2020)
52 KEY UPCOMING EVENTS
53 KEY REGULATORY EVENTS
53 Théa Invests Further In UK With Latest Dry Eye Launch
53 Thea Pharmaceuticals Adds Reusable Eye Compress To UK Blepha Range
53 Viatris Readies Restasis Launch – So Where Are The Others?
53 Oyster Point Prepares Major Push For New Dry Eye Drug
54 Bausch Health Lubricates Bausch + Lomb’s Pending Separation With Hydration Eye Drops Launch
54 Japan’s Rohto Offers Brits Dry Eye Relief As Screen Time Soars
55 PROBABILITY OF SUCCESS
56 LICENSING AND ASSET ACQUISITION DEALS
56 Acquisition By HLB Group To Speed Up GtreeBNT’s Programs
56 Stada Partners With NTC For Ophthalmic Brands In MENA
56 Deal For TheraTears Emphasizes Prestige Is A Consumer Health Business, Akorn Isn’t
58 REVENUE OPPORTUNITY
59 CLINICAL TRIAL LANDSCAPE
60 Sponsors by status
61 Sponsors by phase
62 Recent events
65 BIBLIOGRAPHY
66 APPENDIX
LIST OF FIGURES
17 Figure 1: Trends in prevalent cases of dry eye disease, 2020–29
21 Figure 2: Overview of pipeline drugs for dry eye disease in the US
21 Figure 3: Pipeline drugs for dry eye disease, by company
22 Figure 4: Pipeline drugs for dry eye disease, by drug type
22 Figure 5: Pipeline drugs for dry eye disease, by classification
31 Figure 6: CyclASol for Dry Eye (December 21, 2021): Phase III – ESSENCE-2
32 Figure 7: OTX-DED for Dry Eye (December 6, 2021): Phase II – OTX-DED-2020-201
34 Figure 8: OTX-CSI for Dry Eye (October 22, 2021): Phase II – w/Vehicle
35 Figure 9: NovaTears for Dry Eye (September 30, 2021): Phase III – MOJAVE
37 Figure 10: AR-15512 for Dry Eye (September 15, 2021): Phase IIb – COMET-1
39 Figure 11: NovaTears for Dry Eye (April 13, 2021): Phase III – GOBI
41 Figure 12: RGN-259 for Dry Eye (March 18, 2021): Phase III – ARISE-3 (US)
43 Figure 13: Visomitin for Dry Eye (February 22, 2021): Phase III – VISTA-2
44 Figure 14: CyclASol for Dry Eye (January 11, 2021): Phase IIb/III – CYS-003 (ESSENCE)
46 Figure 15: Reproxalap for Dry Eye (January 7, 2021): Phase III – TRANQUILITY
48 Figure 16: NovaTears for Dry Eye (December 22, 2020): Phase II – SEECASE
49 Figure 17: PL-9643 for Dry Eye (December 15, 2020): Phase II – PL9643-201
51 Figure 18: Voclosporin Ophthalmic Solution (VOS) for Dry Eye (November 2, 2020): Phase II/III – AUDREY
52 Figure 19: Key upcoming events in dry eye disease
55 Figure 20: Probability of success in the dry eye pipeline
59 Figure 21: Clinical trials in dry eye disease
59 Figure 22: Top 10 drugs for clinical trials in dry eye disease
60 Figure 23: Top 10 companies for clinical trials in dry eye disease
60 Figure 24: Trial locations in dry eye disease
61 Figure 25: Dry eye disease trials status
62 Figure 26: Dry eye disease trials sponsors, by phase
LIST OF TABLES
15 Table 1: Prevalent cases of dry eye disease, 2020–29
19 Table 2: Marketed drugs for dry eye disease
23 Table 3: Pipeline drugs for dry eye disease in the US
29 Table 4: ST-100 for Dry Eye (January 3, 2022)
30 Table 5: CyclASol for Dry Eye (December 21, 2021)
31 Table 6: OTX-DED for Dry Eye (December 6, 2021)
33 Table 7: OTX-CSI for Dry Eye (October 22, 2021)
34 Table 8: NovaTears for Dry Eye (September 30, 2021)
36 Table 9: AR-15512 for Dry Eye (September 15, 2021)
38 Table 10: NovaTears for Dry Eye (April 13, 2021)
40 Table 11: RGN-259 for Dry Eye (March 18, 2021)
42 Table 12: Visomitin for Dry Eye (February 22, 2021)
43 Table 13: CyclASol for Dry Eye (January 11, 2021)
45 Table 14: Reproxalap for Dry Eye (January 7, 2021)
47 Table 15: NovaTears for Dry Eye (December 22, 2020)
48 Table 16: PL-9643 for Dry Eye (December 15, 2020)
50 Table 17: Voclosporin Ophthalmic Solution (VOS) for Dry Eye (November 2, 2020)
58 Table 18: Historical global sales, by drug ($m), 2017–21
58 Table 19: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Esophageal Cancer 
Sign up to the